Résumé
Hepatocellular carcinoma (HCC) is one of the highly malignant tumors in the world.Clinically,its onset is occult,its progression is rapid and its prognosis is poor.At present,radical surgery and other adjuvant therapies,such as percutaneous hepatic artery chemoembolization and molecular targeted therapy,are the primary therapeutic means.Although these treatments have certain curative effect,the overall survival rate of HCC patients is still unsatisfactory.Using monoclonal antibody as its carrier,131I-labeled metuximab (Licartin) is a radioactive isotope immune drug;it can specifically conjugate with the surface antigen of HCC cell,then,through both immune blocking and β ray radiation ways,produce dual targeted killing effect on HCC cells.Therefore,Licartin provides a new choice for the treatment of HCC.This paper aims to make a comprehensive review concerning the clinical application and research progress of 131I-labeled metuximab in treating HCC.